<DOC>
	<DOCNO>NCT02171143</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics ( PK ) single , ascend , intravenous ( IV ) dose ASP2409 patient Rheumatoid Arthritis ( RA ) methotrexate ( MTX ) evaluate pharmacodynamics ( PD ) ASP2409 .</brief_summary>
	<brief_title>A Dose Escalation Study Assess Safety , Tolerability Pharmacokinetics ASP2409 Following Single Intravenous Dose Patients With Rheumatoid Arthritis Methotrexate</brief_title>
	<detailed_description>This dose-escalation study . Sequential cohort subject receive increase dos ASP2409 match placebo . Subjects cohort stay confine unit 3 day . All subject schedule outpatient visit follow minimum 90 day .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Subject weigh least 50 kg . Subject body mass index ( BMI ) ≤ 35 kg/m2 . Subject 's 12lead electrocardiogram ( ECG ) result normal Screening Day 1 , abnormal , abnormality clinically significant Female subject must either : Of nonchildbearing potential : 1. postmenopausal ( define least 1 year without menses ) prior Screening , 2. document surgically sterile status post hysterectomy ( least 1 month prior Screening ) . Or , childbearing potential : 1. must negative serum pregnancy test Screening negative urine pregnancy test Day 1 . 2. must use two form birth control ( least one must barrier method ) start Screening throughout Treatment Observation Period , ≥ 120 day final study drug administration . 3 . Acceptable form include : 1 . Established use oral , injected implant hormonal method contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . 3 . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/ cream/suppository . Female subject must breastfeed Screening Treatment Observation period ≥ 120 day final study drug administration . Female subject must donate ovum start Screening throughout Treatment Observation period ≥ 120 day final study drug administration . Male subject must donate sperm start Screening throughout Treatment Observation period least ≥ 120 day final study drug administration . Male subject female spouse/partners childbearing potential must use highly effective contraception consist two form birth control ( one must barrier method ) start Screening continue throughout Treatment Observation period ≥ 120 day final study drug administration . Subject Rheumatoid Arthritis ( RA ) diagnose accord 1987 revised criterion American College Rheumatology ( ACR ) ≥ 6 month prior Screening . Subject meet ACR 1991 revise criterion Global Functional Status RA , Class I , II III Screening . Subject MUST concomitant methotrexate ( MTX ) : ≥ 3 month prior study drug infusion , AND stable dose ( 10 25 mg/week ) ≥ 28 day prior study drug infusion throughout study . Subjects follow medication must remain stable regimen : nonsteroidal antiinflammatory drug ( NSAIDs ) , selective cyclooxygenase2 ( COX2 ) inhibitor , hydroxychloroquine ( Plaquenil® ) , sulfasalazine , oral corticosteroid ( ≤ 10 mg prednisone , equivalent , daily ) low dose opioids ( ≤ 30 mg oral morphine , equivalent , daily ) ≥ 28 day prior Screening remain throughout Treatment Observation Period . ( The start Plaquenil sulfasalazine must ≥ 2 month prior study drug infusion . ) Subject highly likely comply protocol complete study . Subject ongoing clinically significant systemic disease uncompensated heart failure , uncontrolled diabetes mellitus , severe hepatic failure severe pulmonary disease . Subject history malignancy except adequatelytreated , nonmelanoma skin cancer adequatelytreated insitu cervical cancer . Subject history severe allergic anaphylactic reaction . Subject history consume 14 unit alcoholic beverage per week history alcoholism drug/chemical/substance abuse within past 6 month prior Screening ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) . Subject positive test alcohol drug abuse ( exclude drug prescribe subject ) Screening Day 1 . Subject has/had viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior Day 1 . Subject past history serious opportunistic infection . Subject know positive human immunodeficiency virus ( HIV ) antibody . Subject positive tuberculosis ( TB ) skin test Quantiferon Gold test Screening . Subject positive test hepatitis C antibody , positive test hepatitis B surface antigen ( HBsAg ) , positive hepatitis B core antibody Screening . Subject 's laboratory test result Screening : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) , ˃ 2 time upper limit normal , AND/OR outside normal limit consider Investigator clinically significant regard remain perprotocol laboratory test . Subject receive live live attenuate vaccine within 30 day prior study drug infusion . Subject receive systemic immunosuppressant agent , ( MTX ) stable steroid regimen , within 2 month prior study drug infusion . Subject previously receive antibody therapeutic biologic product within 56 day 5 halflives , whichever longer , prior study drug infusion . Subject previously participate interventional clinical study receive experimental agent within 56 day 5 halflives , whichever longer , prior study drug infusion . Subject participate another clinical trial participate another dose group current trial . Subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Day 1 . Subject take Orencia® ( abatacept ) , Nulojix® ( belatacept ) CTLA4Ig molecule . Subject condition precludes subject 's participation trial . Subject history prolong QT syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>ASP2409</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>methotrexate</keyword>
</DOC>